



WELCOME TO THE FUTURE OF AMD CARE

New technology eliminates virtually every barrier to simple, objective, in-office diagnosis and management of age-related macular degeneration.



The original AdaptDx automated dark adaptometer was introduced in 2014 and has since been used by more than 1,000 eye care professionals to identify and monitor AMD. Since then, dark adaptometry has significantly lessened the profession's reliance on risk assessment by providing a tool that helps clinicians diagnose AMD with 90% accuracy. In addition, the AdaptDx has revolutionized AMD management, leading to a number of publications that discuss in detail new practice guidelines and draw attention to evolving standards of care.

Leading Optometrists Unite to Develop Practical Guidelines for AMD Diagnosis and Management

The commercialization of dark adaptation sparked intense discussion over the course of several years, especially after a large peer-reviewed study revealed that subjective dilated fundus exam testing and photography are not reliable means to detect AMD—even in patients who have large drusen.¹ Meanwhile, it became increasingly apparent that the AdaptDx removes the guesswork from diagnosing AMD very early

in the disease process. This led to a swift domino effect and, in a few short years, the introduction of dark adaptation in optometric practice was widely recognized as a tipping point, leading to the formation of a group of clinicians devoted to changing AMD care and calling for profession-wide change.

In “Practical Strategies for Preventing Blindness Caused by AMD,” the third in a series of annual reports aimed at reducing avoidable vision loss, 27 AMD Ambassadors released the “AMD Manifesto,” which includes five essential practice guidelines for modern AMD diagnosis and management:

- 1 The goal of managing AMD is to preserve visual function—not to wait until vision has already been lost.
- 2 Dark adaptation testing can overcome the practical challenges associated with diagnosing AMD using only traditional subjective clinical assessment.
- 3 Optometrists must establish improved practice protocols to proactively identify early disease and monitor it on a regular basis to ensure that CNV is detected as soon as it occurs.
- 4 Optometrists can, and should, recommend treatments that make a meaningful difference.
- 5 The treatment of AMD should be initiated at first detection, regardless of the stage.

Breakthrough Technology Makes It Easy for Everyone

In light of the recently declared need to embrace dark adaptation in optometric settings, MacuLogix was tasked with ensuring that the technology was accessible and that there were no significant obstacles to adoption. As eye care providers were developing best practices, MacuLogix scientists and engineers continued to innovate, solving any practical challenges that could potentially stand in the way of preventing avoidable blindness due to AMD.

In January 2020, the AMD Ambassadors got a first look at a next-generation unit called the AdaptDx Pro™ guided by Theia.™ This revolutionary new device includes all the functionality of the company’s tabletop dark adaptometer in a wearable headset that requires

no darkroom and features an artificial intelligence-driven onboard technician named Theia.

The self-contained wearable headset was custom-designed and tested for patient comfort and produces the same results as the company’s tabletop dark adaptometer. In fact, it creates a comfortable, personal dark room so patients can take the test anywhere in the office, in any light—making it easier than ever to fit dark adaptation testing into any practice workflow. Not only is the entire experience improved for everyone involved, but the addition of Theia’s gentle coaching helps ensure accuracy of test results.

After the office technician selects the testing protocol and places the device on the patient, Theia takes over to facilitate a reliable, consistent test by using automated instructions and adaptive feedback spoken directly to the patient.

The AdaptDx Pro is truly a revolutionary way to quickly and effectively measure dark adaptation in virtually any clinical setting, without taking up too much staff or doctor time.

A Better Future for Your Patients and Your Practice Starts Today

Since 2014, ODs have shared their real-world accounts of how dark adaptation technology has transformed their practices and the lives of countless patients. MacuLogix has used this insight to create the AdaptDx Pro—a one-of-a-kind medical device that improves the testing experience and makes modern AMD diagnosis and management practical in almost any eye care practice. **Are you ready to join your colleagues in embracing progress and improving AMD care by welcoming Theia and the AdaptDx Pro into your practice?**



AdaptDx
PRO
Guided by Theia™

¹ Neely DC, Bray KJ, Huisinigh CE, Clark ME, McGwin G, Owsley C. Prevalence of undiagnosed age-related macular degeneration in primary eye care. *JAMA Ophthalmol.* 2017;135(6):570-5.